Harvard Bioscience (HBIO) Gains from Sales and Divestitures (2017 - 2023)

Harvard Bioscience (HBIO) has 7 years of Gains from Sales and Divestitures data on file, last reported at $316210.0 in Q4 2023.

• Gains from Sales and Divestitures for Q4 2023 came in at $316210.0, down 21.21% year-over-year; the trailing twelve-month figure through Dec 2023 was $316210.0 (down 21.21% YoY), and the FY2023 annual result was $316210.0, down 21.21% from the prior year.
• Gains from Sales and Divestitures advanced to $316210.0 in Q4 2023 per HBIO's latest filing, from $115976.0 in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $1.2 million in Q4 2021 and troughed at $115976.0 in Q2 2023.
• A 5-year average of $407903.2 and a median of $278207.5 in 2020 frame the typical range for Gains from Sales and Divestitures.
• The sharpest annual moves came in 2019 and 2022: Gains from Sales and Divestitures soared 21439.49% in 2019, then sank 70.95% in 2022.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $813762.0 in 2019, then tumbled by 70.48% to $240205.0 in 2020, then soared by 386.03% to $1.2 million in 2021, then tumbled by 65.63% to $401308.0 in 2022, then retreated by 21.21% to $316210.0 in 2023.
• Business Quant data shows HBIO's Gains from Sales and Divestitures at $316210.0 in Q4 2023, $115976.0 in Q3 2023, and $115976.0 in Q2 2023.